NCT07025226

Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

MC230715 Pilot Study of the Mechanistic Feedback From CNS Tumors With Latent Residual Disease to Guide Individualized Therapies

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin and temozolomide work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the tumor have been made (residual disease). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply, which may help keep tumor cells from growing. Quercetin and fisetin are compounds found in plants. They have antioxidant and anti-inflammatory properties and help remove senescent cells, older or damaged cells that have stopped dividing but don't die off as they should and build up in tissues over time. Senescent cells may cause inflammation or damage to nearby healthy cells. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. Giving medication combinations of dasatinib, quercetin, fisetin and temozolomide may be safe, tolerable and/or effective in treating patients with previously treated glioma with residual disease.

Conditions

• Glioma

Interventions

Type	Name	Description
PROCEDURE	Biospecimen Collection	Undergo blood and CSF sample collection
DRUG	Dasatinib	Given PO
DRUG	Fisetin	Given PO
DRUG	Fluorodopa F 18	Undergo 18F-DOPA-PET scan
PROCEDURE	Magnetic Resonance Imaging	Undergo MRI
OTHER	Patient Observation	Receive rest and take no treatment
PROCEDURE	Positron Emission Tomography	Undergo 18F-DOPA-PET scan
DRUG	Quercetin	Given PO
DRUG	Temozolomide	Given PO

Timeline

• Start date: 2025-08-12
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2025-06-17
• Last updated: 2026-01-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study